Building on existing integrations with cloud leaders AWS and Google Cloud and collaborations with Arcadia and TD2, Atropos Health is now partnering with Merck. This new collaboration will tap Atropos Health’s GENEVA OS (Generative Evidence Acceleration Operating System) and related tools with the aim of speeding the generation of real-world evidence.
Under the agreement, Merck’s data science and RWE teams will use Atropos Health services including GENEVA OS and other tools. The aim is multifaceted — generating RWE, replicating studies, and producing rapid RWD analytics. The press release describes the goal of achieving 48-hour turnaround on many studies.
“Our partnership with Merck highlights the value and impact of automation and high-quality RWE. The Atropos platform, now leveraged by 8 of the top 11 global life sciences companies, will enable Merck to accelerate evidence and insight to bring life-saving treatments to patients,” said Brigham Hyde, Ph.D., CEO and co-founder at Atropos Health, via email.
Atropos Health will provide Merck access to a federated healthcare data network with more than 300 million patient records (the Atropos Evidence Network).
Atropos Health recently launched ChatRWD, a generative AI application for delivering observational studies on healthcare data.
In May 2024, Atropos Health raised $33 million in funding, with participation from Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund.
Filed Under: clinical trials, Drug Discovery, machine learning and AI
